Hyderabad, Nov 14 (PTI) Laurus Labs Limited today saidit received Establishment Inspection Report (EIR) from the USFood and Drug Administration(USFDA) for its API (activepharma ingredients) plants located at Visakhapatnam in AndhraPradesh.
"Laurus Labs Limited has received the EstablishmentInspection Report (EIR) from USFDA for its unit 1 and 3,located at Parawada, Visakhapatnam, for the inspectionconducted in August 2017," the drug maker said in a statement.
The company had earlier said that the US regulatorcompleted the inspection with two observations which were in "procedural in nature".
The city-based pharma company had also said it was aregular surveillance audit by the USFDA and no data integrityissues were observed.
Laurus Lab shares today closed almost flat at Rs524.30 apiece on BSE. PTI GDKNRB.
This is unedited, unformatted feed from the Press Trust of India wire.